Under the terms of the agreement, Cephalon will provide up to A $15 million to ChemGenex in return for a note that is convertible at A $0.50 per share.
Cephalon also entered into option agreements with two of ChemGenex's major shareholders, Stragen International N.V. and Merck Sante S.A.S.